KRAS and lung carcinoma: Given that 30%–40% of patients with KRAS-mutated lung cancer have co-existing TP53 mutations and poor prognoses, we evaluated the effect of WEE1 downregulation in KRAS-mutated NSCLC cell lines with or without TP53 mutations.